Login to Your Account

Gemin X Can Take Lead Drug Through Phase II With $65M

By Karen Pihl-Carey

Friday, May 20, 2005
Raising $65.2 million in its largest financing to date, Gemin X Biotechnologies Inc. plans to advance its lead oncology candidate through Phase II studies. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription